Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 279

1.

PI4KIIIβ is a therapeutic target in chromosome 1q-amplified lung adenocarcinoma.

Tan X, Banerjee P, Pham EA, Rutaganira FUN, Basu K, Bota-Rabassedas N, Guo HF, Grzeskowiak CL, Liu X, Yu J, Shi L, Peng DH, Rodriguez BL, Zhang J, Zheng V, Duose DY, Solis LM, Mino B, Raso MG, Behrens C, Wistuba II, Scott KL, Smith M, Nguyen K, Lam G, Choong I, Mazumdar A, Hill JL, Gibbons DL, Brown PH, Russell WK, Shokat K, Creighton CJ, Glenn JS, Kurie JM.

Sci Transl Med. 2020 Jan 22;12(527). pii: eaax3772. doi: 10.1126/scitranslmed.aax3772.

PMID:
31969487
2.

Pan-cancer molecular subtypes revealed by mass-spectrometry-based proteomic characterization of more than 500 human cancers.

Chen F, Chandrashekar DS, Varambally S, Creighton CJ.

Nat Commun. 2019 Dec 12;10(1):5679. doi: 10.1038/s41467-019-13528-0.

3.

Proteomic signatures of clear cell renal cell carcinoma.

Creighton CJ.

Nat Rev Nephrol. 2019 Nov 28. doi: 10.1038/s41581-019-0233-5. [Epub ahead of print] No abstract available.

PMID:
31780818
4.

ZEB1/NuRD complex suppresses TBC1D2b to stimulate E-cadherin internalization and promote metastasis in lung cancer.

Manshouri R, Coyaud E, Kundu ST, Peng DH, Stratton SA, Alton K, Bajaj R, Fradette JJ, Minelli R, Peoples MD, Carugo A, Chen F, Bristow C, Kovacs JJ, Barton MC, Heffernan T, Creighton CJ, Raught B, Gibbons DL.

Nat Commun. 2019 Nov 12;10(1):5125. doi: 10.1038/s41467-019-12832-z.

5.

A CTC-Cluster-Specific Signature Derived from OMICS Analysis of Patient-Derived Xenograft Tumors Predicts Outcomes in Basal-Like Breast Cancer.

Thangavel H, De Angelis C, Vasaikar S, Bhat R, Jolly MK, Nagi C, Creighton CJ, Chen F, Dobrolecki LE, George JT, Kumar T, Abdulkareem NM, Mao S, Nardone A, Rimawi M, Osborne CK, Lewis MT, Levine H, Zhang B, Schiff R, Giuliano M, Trivedi MV.

J Clin Med. 2019 Oct 24;8(11). pii: E1772. doi: 10.3390/jcm8111772.

6.

Global impact of somatic structural variation on the DNA methylome of human cancers.

Zhang Y, Yang L, Kucherlapati M, Hadjipanayis A, Pantazi A, Bristow CA, Lee EA, Mahadeshwar HS, Tang J, Zhang J, Seth S, Lee S, Ren X, Song X, Sun H, Seidman J, Luquette LJ, Xi R, Chin L, Protopopov A, Park PJ, Kucherlapati R, Creighton CJ.

Genome Biol. 2019 Oct 15;20(1):209. doi: 10.1186/s13059-019-1818-9.

7.

Correction: Alterations in Wnt- and/or STAT3 signaling pathways and the immune microenvironment during metastatic progression.

Kim SJ, Garcia-Recio S, Creighton CJ, Perou CM, Rosen JM.

Oncogene. 2020 Jan;39(4):950. doi: 10.1038/s41388-019-1017-x.

PMID:
31558798
8.

Association between plasma diacetylspermine and tumor spermine synthase with outcome in triple negative breast cancer.

Fahrmann JF, Vykoukal J, Fleury A, Tripathi S, Dennison JB, Murage E, Wang P, Yu CY, Capello M, Creighton CJ, Do KA, Long JP, Irajizad E, Peterson C, Katayama H, Disis ML, Arun B, Hanash S.

J Natl Cancer Inst. 2019 Sep 10. pii: djz182. doi: 10.1093/jnci/djz182. [Epub ahead of print]

PMID:
31503278
9.

Correction: Crosstalk from Non-Cancerous Mitochondria Can Inhibit Tumor Properties of Metastatic Cells by Suppressing Oncogenic Pathways.

Kaipparettu BA, Ma Y, Park JH, Lee TL, Zhang Y, Yotnda P, Creighton CJ, Chan WY, Wong LC.

PLoS One. 2019 Aug 22;14(8):e0221671. doi: 10.1371/journal.pone.0221671. eCollection 2019.

10.

Spermidine/spermine N1-acetyltransferase 1 is a gene-specific transcriptional regulator that drives brain tumor aggressiveness.

Thakur VS, Aguila B, Brett-Morris A, Creighton CJ, Welford SM.

Oncogene. 2019 Oct;38(41):6794-6800. doi: 10.1038/s41388-019-0917-0. Epub 2019 Aug 9.

PMID:
31399646
11.

Alterations in Wnt- and/or STAT3 signaling pathways and the immune microenvironment during metastatic progression.

Kim SJ, Garcia-Recio S, Creighton CJ, Perou CM, Rosen JM.

Oncogene. 2019 Aug;38(31):5942-5958. doi: 10.1038/s41388-019-0852-0. Epub 2019 Jul 9. Erratum in: Oncogene. 2019 Sep 26;:.

12.

JNK1/2 represses Lkb1-deficiency-induced lung squamous cell carcinoma progression.

Liu J, Wang T, Creighton CJ, Wu SP, Ray M, Janardhan KS, Willson CJ, Cho SN, Castro PD, Ittmann MM, Li JL, Davis RJ, DeMayo FJ.

Nat Commun. 2019 May 14;10(1):2148. doi: 10.1038/s41467-019-09843-1.

13.

Reply to Liu et al.: ALK5-mediated tumor suppressor signaling through SMAD2 and SMAD3 in the uterus.

Monsivais D, Kriseman M, Creighton CJ, Matzuk MM.

Proc Natl Acad Sci U S A. 2019 May 7;116(19):9166-9167. doi: 10.1073/pnas.1904354116. No abstract available.

14.

TP53 Status as a Determinant of Pro- vs Anti-Tumorigenic Effects of Estrogen Receptor-Beta in Breast Cancer.

Mukhopadhyay UK, Oturkar CC, Adams C, Wickramasekera N, Bansal S, Medisetty R, Miller A, Swetzig WM, Silwal-Pandit L, Børresen-Dale AL, Creighton CJ, Park JH, Konduri SD, Mukhopadhyay A, Caradori A, Omilian A, Bshara W, Kaipparettu BA, Das GM.

J Natl Cancer Inst. 2019 Nov 1;111(11):1202-1215. doi: 10.1093/jnci/djz051.

15.

Spatially Restricted Stromal Wnt Signaling Restrains Prostate Epithelial Progenitor Growth through Direct and Indirect Mechanisms.

Wei X, Zhang L, Zhou Z, Kwon OJ, Zhang Y, Nguyen H, Dumpit R, True L, Nelson P, Dong B, Xue W, Birchmeier W, Taketo MM, Xu F, Creighton CJ, Ittmann MM, Xin L.

Cell Stem Cell. 2019 May 2;24(5):753-768.e6. doi: 10.1016/j.stem.2019.03.010. Epub 2019 Apr 11.

PMID:
30982770
16.

Abnormal oxidative metabolism in a quiet genomic background underlies clear cell papillary renal cell carcinoma.

Xu J, Reznik E, Lee HJ, Gundem G, Jonsson P, Sarungbam J, Bialik A, Sanchez-Vega F, Creighton CJ, Hoekstra J, Zhang L, Sajjakulnukit P, Kremer D, Tolstyka Z, Casuscelli J, Stirdivant S, Tang J, Schultz N, Jeng P, Dong Y, Su W, Cheng EH, Russo P, Coleman JA, Papaemmanuil E, Chen YB, Reuter VE, Sander C, Kennedy SR, Hsieh JJ, Lyssiotis CA, Tickoo SK, Hakimi AA.

Elife. 2019 Apr 1;8. pii: e38986. doi: 10.7554/eLife.38986.

17.

Functional Heterogeneity of Mouse Prostate Stromal Cells Revealed by Single-Cell RNA-Seq.

Kwon OJ, Zhang Y, Li Y, Wei X, Zhang L, Chen R, Creighton CJ, Xin L.

iScience. 2019 Mar 29;13:328-338. doi: 10.1016/j.isci.2019.02.032. Epub 2019 Mar 2.

18.

MAPK4 overexpression promotes tumor progression via noncanonical activation of AKT/mTOR signaling.

Wang W, Shen T, Dong B, Creighton CJ, Meng Y, Zhou W, Shi Q, Zhou H, Zhang Y, Moore DD, Yang F.

J Clin Invest. 2019 Mar 1;129(3):1015-1029. doi: 10.1172/JCI97712. Epub 2019 Jan 28.

19.

Uterine double-conditional inactivation of Smad2 and Smad3 in mice causes endometrial dysregulation, infertility, and uterine cancer.

Kriseman M, Monsivais D, Agno J, Masand RP, Creighton CJ, Matzuk MM.

Proc Natl Acad Sci U S A. 2019 Feb 26;116(9):3873-3882. doi: 10.1073/pnas.1806862116. Epub 2019 Jan 16.

20.

Molecular Correlates of Metastasis by Systematic Pan-Cancer Analysis Across The Cancer Genome Atlas.

Chen F, Zhang Y, Varambally S, Creighton CJ.

Mol Cancer Res. 2019 Feb;17(2):476-487. doi: 10.1158/1541-7786.MCR-18-0601. Epub 2018 Nov 6.

PMID:
30401717
21.

Mammary Precancerous Stem and Non-Stem Cells Evolve into Cancers of Distinct Subtypes.

Bu W, Liu Z, Jiang W, Nagi C, Huang S, Edwards DP, Jo E, Mo Q, Creighton CJ, Hilsenbeck SG, Leavitt AD, Lewis MT, Wong STC, Li Y.

Cancer Res. 2019 Jan 1;79(1):61-71. doi: 10.1158/0008-5472.CAN-18-1087. Epub 2018 Nov 6.

22.

Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer.

Wang Y, Xu X, Maglic D, Dill MT, Mojumdar K, Ng PK, Jeong KJ, Tsang YH, Moreno D, Bhavana VH, Peng X, Ge Z, Chen H, Li J, Chen Z, Zhang H, Han L, Du D, Creighton CJ, Mills GB; Cancer Genome Atlas Research Network, Camargo F, Liang H.

Cell Rep. 2018 Oct 30;25(5):1304-1317.e5. doi: 10.1016/j.celrep.2018.10.001.

23.

MicroRNAs as prognostic markers in prostate cancer.

Suer I, Guzel E, Karatas OF, Creighton CJ, Ittmann M, Ozen M.

Prostate. 2019 Feb;79(3):265-271. doi: 10.1002/pros.23731. Epub 2018 Oct 21.

PMID:
30345533
24.

Integrated Multi-omic Analysis of Esthesioneuroblastomas Identifies Two Subgroups Linked to Cell Ontogeny.

Classe M, Yao H, Mouawad R, Creighton CJ, Burgess A, Allanic F, Wassef M, Leroy X, Verillaud B, Mortuaire G, Bielle F, Le Tourneau C, Kurtz JE, Khayat D, Su X, Malouf GG.

Cell Rep. 2018 Oct 16;25(3):811-821.e5. doi: 10.1016/j.celrep.2018.09.047.

25.

miR-205 Regulates Basal Cell Identity and Stem Cell Regenerative Potential During Mammary Reconstitution.

Lu Y, Cao J, Napoli M, Xia Z, Zhao N, Creighton CJ, Li W, Chen X, Flores ER, McManus MT, Rosen JM.

Stem Cells. 2018 Dec;36(12):1875-1889. doi: 10.1002/stem.2914. Epub 2018 Oct 31.

26.

The epithelial-to-mesenchymal transition activator ZEB1 initiates a prometastatic competing endogenous RNA network.

Tan X, Banerjee P, Liu X, Yu J, Gibbons DL, Wu P, Scott KL, Diao L, Zheng X, Wang J, Jalali A, Suraokar M, Fujimoto J, Behrens C, Liu X, Liu CG, Creighton CJ, Wistuba II, Kurie JM.

J Clin Invest. 2018 Jul 2;128(7):3198. doi: 10.1172/JCI122740. Epub 2018 Jul 2. No abstract available.

27.

Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer.

Lei JT, Shao J, Zhang J, Iglesia M, Chan DW, Cao J, Anurag M, Singh P, He X, Kosaka Y, Matsunuma R, Crowder R, Hoog J, Phommaly C, Goncalves R, Ramalho S, Peres RMR, Punturi N, Schmidt C, Bartram A, Jou E, Devarakonda V, Holloway KR, Lai WV, Hampton O, Rogers A, Tobias E, Parikh PA, Davies SR, Li S, Ma CX, Suman VJ, Hunt KK, Watson MA, Hoadley KA, Thompson EA, Chen X, Kavuri SM, Creighton CJ, Maher CA, Perou CM, Haricharan S, Ellis MJ.

Cell Rep. 2018 Aug 7;24(6):1434-1444.e7. doi: 10.1016/j.celrep.2018.07.009.

28.

The clinical applications of The Cancer Genome Atlas project for bladder cancer.

Creighton CJ.

Expert Rev Anticancer Ther. 2018 Oct;18(10):973-980. doi: 10.1080/14737140.2018.1508999. Epub 2018 Aug 13. Review.

29.

TMEM106B drives lung cancer metastasis by inducing TFEB-dependent lysosome synthesis and secretion of cathepsins.

Kundu ST, Grzeskowiak CL, Fradette JJ, Gibson LA, Rodriguez LB, Creighton CJ, Scott KL, Gibbons DL.

Nat Commun. 2018 Jul 16;9(1):2731. doi: 10.1038/s41467-018-05013-x.

30.

In vivo screening identifies GATAD2B as a metastasis driver in KRAS-driven lung cancer.

Grzeskowiak CL, Kundu ST, Mo X, Ivanov AA, Zagorodna O, Lu H, Chapple RH, Tsang YH, Moreno D, Mosqueda M, Eterovic K, Fradette JJ, Ahmad S, Chen F, Chong Z, Chen K, Creighton CJ, Fu H, Mills GB, Gibbons DL, Scott KL.

Nat Commun. 2018 Jul 16;9(1):2732. doi: 10.1038/s41467-018-04572-3.

31.

A Pan-Cancer Compendium of Genes Deregulated by Somatic Genomic Rearrangement across More Than 1,400 Cases.

Zhang Y, Yang L, Kucherlapati M, Chen F, Hadjipanayis A, Pantazi A, Bristow CA, Lee EA, Mahadeshwar HS, Tang J, Zhang J, Seth S, Lee S, Ren X, Song X, Sun H, Seidman J, Luquette LJ, Xi R, Chin L, Protopopov A, Li W, Park PJ, Kucherlapati R, Creighton CJ.

Cell Rep. 2018 Jul 10;24(2):515-527. doi: 10.1016/j.celrep.2018.06.025.

32.

Mammary stem cell and macrophage markers are enriched in normal tissue adjacent to inflammatory breast cancer.

Reddy JP, Atkinson RL, Larson R, Burks JK, Smith D, Debeb BG, Ruffell B, Creighton CJ, Bambhroliya A, Reuben JM, Van Laere SJ, Krishnamurthy S, Symmans WF, Brewster AM, Woodward WA.

Breast Cancer Res Treat. 2018 Sep;171(2):283-293. doi: 10.1007/s10549-018-4835-6. Epub 2018 Jun 1.

PMID:
29858753
33.

IL17A Regulates Tumor Latency and Metastasis in Lung Adeno and Squamous SQ.2b and AD.1 Cancer.

You R, DeMayo FJ, Liu J, Cho SN, Burt BM, Creighton CJ, Casal RF, Lazarus DR, Lu W, Tung HY, Yuan X, Hill-McAlester A, Kim M, Perusich S, Cornwell L, Rosen D, Song LZ, Paust S, Diehl G, Corry D, Kheradmand F.

Cancer Immunol Res. 2018 Jun;6(6):645-657. doi: 10.1158/2326-6066.CIR-17-0554. Epub 2018 Apr 13.

34.

Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas.

Campbell JD, Yau C, Bowlby R, Liu Y, Brennan K, Fan H, Taylor AM, Wang C, Walter V, Akbani R, Byers LA, Creighton CJ, Coarfa C, Shih J, Cherniack AD, Gevaert O, Prunello M, Shen H, Anur P, Chen J, Cheng H, Hayes DN, Bullman S, Pedamallu CS, Ojesina AI, Sadeghi S, Mungall KL, Robertson AG, Benz C, Schultz A, Kanchi RS, Gay CM, Hegde A, Diao L, Wang J, Ma W, Sumazin P, Chiu HS, Chen TW, Gunaratne P, Donehower L, Rader JS, Zuna R, Al-Ahmadie H, Lazar AJ, Flores ER, Tsai KY, Zhou JH, Rustgi AK, Drill E, Shen R, Wong CK; Cancer Genome Atlas Research Network, Stuart JM, Laird PW, Hoadley KA, Weinstein JN, Peto M, Pickering CR, Chen Z, Van Waes C.

Cell Rep. 2018 Apr 3;23(1):194-212.e6. doi: 10.1016/j.celrep.2018.03.063.

35.

Reprogramming of the estrogen responsive transcriptome contributes to tamoxifen-dependent protection against tumorigenesis in the p53 null mammary epithelial cells.

Palaniappan M, Edwards D, Creighton CJ, Medina D, Conneely OM.

PLoS One. 2018 Mar 28;13(3):e0194913. doi: 10.1371/journal.pone.0194913. eCollection 2018.

36.

Fibroblast growth factor receptor signaling plays a key role in transformation induced by the TMPRSS2/ERG fusion gene and decreased PTEN.

Shao L, Wang J, Karatas OF, Feng S, Zhang Y, Creighton CJ, Ittmann M.

Oncotarget. 2018 Feb 12;9(18):14456-14471. doi: 10.18632/oncotarget.24470. eCollection 2018 Mar 6.

37.

Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer.

Nair A, Chung HC, Sun T, Tyagi S, Dobrolecki LE, Dominguez-Vidana R, Kurley SJ, Orellana M, Renwick A, Henke DM, Katsonis P, Schmitt E, Chan DW, Li H, Mao S, Petrovic I, Creighton CJ, Gutierrez C, Dubrulle J, Stossi F, Tyner JW, Lichtarge O, Lin CY, Zhang B, Scott KL, Hilsenbeck SG, Sun J, Yu X, Osborne CK, Schiff R, Christensen JG, Shields DJ, Rimawi MF, Ellis MJ, Shaw CA, Lewis MT, Westbrook TF.

Nat Med. 2018 May;24(4):505-511. doi: 10.1038/nm.4507. Epub 2018 Mar 26.

38.

GPCRs profiling and identification of GPR110 as a potential new target in HER2+ breast cancer.

Bhat RR, Yadav P, Sahay D, Bhargava DK, Creighton CJ, Yazdanfard S, Al-Rawi A, Yadav V, Qin L, Nanda S, Sethunath V, Fu X, De Angelis C, Narkar VA, Osborne CK, Schiff R, Trivedi MV.

Breast Cancer Res Treat. 2018 Jul;170(2):279-292. doi: 10.1007/s10549-018-4751-9. Epub 2018 Mar 24.

39.

Atrx inactivation drives disease-defining phenotypes in glioma cells of origin through global epigenomic remodeling.

Danussi C, Bose P, Parthasarathy PT, Silberman PC, Van Arnam JS, Vitucci M, Tang OY, Heguy A, Wang Y, Chan TA, Riggins GJ, Sulman EP, Lang F, Creighton CJ, Deneen B, Miller CR, Picketts DJ, Kannan K, Huse JT.

Nat Commun. 2018 Mar 13;9(1):1057. doi: 10.1038/s41467-018-03476-6.

40.

Osteoblast-Secreted Factors Mediate Dormancy of Metastatic Prostate Cancer in the Bone via Activation of the TGFβRIII-p38MAPK-pS249/T252RB Pathway.

Yu-Lee LY, Yu G, Lee YC, Lin SC, Pan J, Pan T, Yu KJ, Liu B, Creighton CJ, Rodriguez-Canales J, Villalobos PA, Wistuba II, de Nadal E, Posas F, Gallick GE, Lin SH.

Cancer Res. 2018 Jun 1;78(11):2911-2924. doi: 10.1158/0008-5472.CAN-17-1051. Epub 2018 Mar 7.

41.

Pan-Cancer Molecular Classes Transcending Tumor Lineage Across 32 Cancer Types, Multiple Data Platforms, and over 10,000 Cases.

Chen F, Zhang Y, Gibbons DL, Deneen B, Kwiatkowski DJ, Ittmann M, Creighton CJ.

Clin Cancer Res. 2018 May 1;24(9):2182-2193. doi: 10.1158/1078-0432.CCR-17-3378. Epub 2018 Feb 9.

42.

A Landscape of Metabolic Variation across Tumor Types.

Reznik E, Luna A, Aksoy BA, Liu EM, La K, Ostrovnaya I, Creighton CJ, Hakimi AA, Sander C.

Cell Syst. 2018 Mar 28;6(3):301-313.e3. doi: 10.1016/j.cels.2017.12.014. Epub 2018 Jan 27.

43.

Change in Neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma.

Lalani AA, Xie W, Martini DJ, Steinharter JA, Norton CK, Krajewski KM, Duquette A, Bossé D, Bellmunt J, Van Allen EM, McGregor BA, Creighton CJ, Harshman LC, Choueiri TK.

J Immunother Cancer. 2018 Jan 22;6(1):5. doi: 10.1186/s40425-018-0315-0.

44.

Making Use of Cancer Genomic Databases.

Creighton CJ.

Curr Protoc Mol Biol. 2018 Jan 16;121:19.14.1-19.14.13. doi: 10.1002/cpmb.49.

45.

The epithelial-to-mesenchymal transition activator ZEB1 initiates a prometastatic competing endogenous RNA network.

Tan X, Banerjee P, Liu X, Yu J, Gibbons DL, Wu P, Scott KL, Diao L, Zheng X, Wang J, Jalali A, Suraokar M, Fujimoto J, Behrens C, Liu X, Liu CG, Creighton CJ, Wistuba II, Kurie JM.

J Clin Invest. 2018 Apr 2;128(4):1267-1282. doi: 10.1172/JCI97225. Epub 2018 Feb 26. Erratum in: J Clin Invest. 2018 Jul 2;128(7):3198.

46.

Genomic classifications of renal cell carcinoma: a critical step towards the future application of personalized kidney cancer care with pan-omics precision.

Hsieh JJ, Le V, Cao D, Cheng EH, Creighton CJ.

J Pathol. 2018 Apr;244(5):525-537. doi: 10.1002/path.5022. Epub 2018 Feb 14. Review.

PMID:
29266437
47.

Coactivation of Estrogen Receptor and IKKβ Induces a Dormant Metastatic Phenotype in ER-Positive Breast Cancer.

El-Shennawy L, Dubrovskyi O, Kastrati I, Danes JM, Zhang Y, Whiteley HE, Creighton CJ, Frasor J.

Cancer Res. 2018 Feb 15;78(4):974-984. doi: 10.1158/0008-5472.CAN-17-1686. Epub 2017 Dec 11.

48.

Influence of the neural microenvironment on prostate cancer.

Coarfa C, Florentin D, Putluri N, Ding Y, Au J, He D, Ragheb A, Frolov A, Michailidis G, Lee M, Kadmon D, Miles B, Smith C, Ittmann M, Rowley D, Sreekumar A, Creighton CJ, Ayala G.

Prostate. 2018 Feb;78(2):128-139. doi: 10.1002/pros.23454. Epub 2017 Nov 13.

49.

WNT-Mediated Regulation of FOXO1 Constitutes a Critical Axis Maintaining Pubertal Mammary Stem Cell Homeostasis.

Sreekumar A, Toneff MJ, Toh E, Roarty K, Creighton CJ, Belka GK, Lee DK, Xu J, Chodosh LA, Richards JS, Rosen JM.

Dev Cell. 2017 Nov 20;43(4):436-448.e6. doi: 10.1016/j.devcel.2017.10.007. Epub 2017 Nov 2.

50.

Daam2 driven degradation of VHL promotes gliomagenesis.

Zhu W, Krishna S, Garcia C, Lin CJ, Mitchell BD, Scott KL, Mohila CA, Creighton CJ, Yoo SH, Lee HK, Deneen B.

Elife. 2017 Oct 20;6. pii: e31926. doi: 10.7554/eLife.31926.

Supplemental Content

Loading ...
Support Center